Takaaki Masuda

Dr. Takaaki Masuda

Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 8740838, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2017 in Cancers
Verified
Journal Article
Open access
PDF file
TMTakaaki Masuda
Takaaki Masuda
NHNaoki Hayashi
Naoki Hayashi
YKYosuke Kuroda
Yosuke Kuroda
SIShuhei Ito
Shuhei Ito
HEHidetoshi Eguchi
Hidetoshi Eguchi
KMKoshi Mimori
Koshi Mimori
MicroRNAs (miRs) are small RNAs that repress mRNA translation, resulting in the degradation of mRNAs and regulation of the expression levels of various genes. Recent studies have shown that aberrant miR expression has a functional role in the initiation and progression of various malignancies, including colorectal cancer (CRC), which is one of the leading causes of cancer-related death worldwide. miRs have also been shown to have applications as diagnostic, prognostic, and predictive biomarkers because of their high tissue specificity, stability, and altered expression in tumor development. In this report, we examined the role of miRs as biomarkers in CRC through a review of meta-analyses and large-scale analyses having strong statistical confidence in the study outcomes. We also discuss current issues in the clinical application of these miRs.

1 July 2002
Verified
Journal Article
Closed access
TMTakaaki Masuda
Takaaki Masuda
HIHiroshi Inoue
Hiroshi Inoue
HSHideto Sonoda
Hideto Sonoda
SMShinji Mine
Shinji Mine
YYYasuji Yoshikawa
Yasuji Yoshikawa
MMMasaki Mori
Masaki Mori

14 January 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
TMTakaaki Masuda
Takaaki Masuda
MNMiwa Noda
Miwa Noda
TKTakahiro Kogawa
Takahiro Kogawa
DKDai Kitagawa
Dai Kitagawa
NHNaoki Hayashi
Naoki Hayashi
KMKoshi Mimori
Koshi Mimori
The formation of premetastatic niches creates a fertile environment for the seeding of disseminated cancer cells in selected secondary organs. This is crucial for the development of metastasis in various malignancies, including breast cancer (BC). We previously reported that the loss of FBXW7 in bone marrow‐derived stromal cells promoted cancer metastasis by increasing the production of the chemokine CCL2, which attracts myeloid‐derived suppressor cells and macrophages to the premetastatic niche. Furthermore, treatment with the CCL2 inhibitor propagermanium (PG), which has been used in Japan as a therapeutic agent against chronic hepatitis B, was shown to block the enhancement of metastasis in FBXW7‐deficient mice through inhibiting the formation of premetastatic niches. Here, we describe a phase I dose‐escalation study of PG used as an antimetastatic drug for perioperative patients with primary BC. The primary end‐point was the percentage of patients who experience dose‐limiting toxicity. Twelve patients were enrolled in the study. Dose‐limiting toxicity was not observed, and the maximum dose was determined to be 90 mg/body/day. The serum concentrations of PG were nearly within the normal range in all observation days. We observed an inverse correlation between FBXW7 mRNA levels in blood and the serum concentrations of CCL2 and interleukin (IL)‐6, in agreement with our previous mouse model. Also, IL‐6 was downregulated in a PG dose‐dependent manner, as observed in mice. Thus, PG was given safely and it is expected to have antimetastatic potential in BC. This trial is registered in the UMIN Clinical Trials Registry as UMIN000022494.

15 February 2006 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HSHideto Sonoda
Hideto Sonoda
HIHiroshi Inoue
Hiroshi Inoue
KOKazuhiko Ogawa
Kazuhiko Ogawa
TUTohru Utsunomiya
Tohru Utsunomiya
TMTakaaki Masuda
Takaaki Masuda
MMMasaki Mori
Masaki Mori
PURPOSE: We previously reported the p27 expression level to be an independent prognostic factor, and a high S-phase kinase-associated protein 2 (Skp2) expression level was significantly correlated with a poor prognosis in patients with gastric cancer. We herein examined the Skp2 expression in breast cancer and attempted to identify any associations between the Skp2 expression status and either the clinicopathologic variables or the patient's prognosis. EXPERIMENTAL DESIGN: We established four Skp2-transfected breast cancer cell lines and assessed the correlations between the Skp2 and p27 expressions using real-time reverse transcription-PCR and a Western blot analysis. We then analyzed the clinicopathologic significance of Skp2 mRNA expression in 169 Japanese patients with breast cancer. An immunohistochemical analysis was also done. RESULTS: The p27 protein expression markedly decreased after Skp2 transfection, whereas no alteration in the p27 mRNA expression was observed. The Skp2 protein expression level as determined by immunohistochemical staining thus showed a significant correlation with the Skp2 mRNA expression (P = 0.001) and a significant inverse correlation with the p27 protein expression (P = 0.042). The patients with a high Skp2 gene expression were significantly younger than those with a low expression (P = 0.002). The prognosis of patients with a high Skp2 expression was significantly (P = 0.022) poorer than for those with a low expression. Moreover, a high expression of Skp2 was an independent variable that correlated with a shorter disease-free survival (relative risk, 3.33; 95% confidence interval, 1.296-8.578; P = 0.013). CONCLUSIONS: The present results suggest that Skp2 may play an important role particularly in young breast cancer, and it is also considered to have strong independent prognostic potential and thus may prove to be a useful target for the treatment of breast cancer.

19 January 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
TMTakaaki Masuda
Takaaki Masuda
YTYusuke Tsuruda
Yusuke Tsuruda
YMYoshihiro Matsumoto
Yoshihiro Matsumoto
HUHiroki Uchida
Hiroki Uchida
KNKeiichi I. Nakayama
Keiichi I. Nakayama
KMKoshi Mimori
Koshi Mimori
Cancer is a leading cause of death worldwide, and the incidence continues to increase. Despite major research aimed at discovering and developing novel and effective anticancer drugs, oncology drug development is a lengthy and costly process, with high attrition rates. Drug repositioning (DR, also referred to as drug repurposing), the process of finding new uses for approved noncancer drugs, has been gaining popularity in the past decade. DR has become a powerful alternative strategy for discovering and developing novel anticancer drug candidates from the existing approved drug space. Indeed, the availability of several large established libraries of clinical drugs and rapid advances in disease biology, genomics/transcriptomics/proteomics and bioinformatics has accelerated the pace of activity‐based, literature‐based and in silico DR, thereby improving safety and reducing costs. However, DR still faces financial obstacles in clinical trials, which could limit its practical use in the clinic. Here, we provide a brief review of DR in cancer and discuss difficulties in the development of DR for clinical use. Furthermore, we introduce some promising DR candidates for anticancer therapy in Japan.

15 November 2003
Verified
Journal Article
Closed access
TMTakaaki Masuda
Takaaki Masuda
HIHiroshi Inoue
Hiroshi Inoue
KNKoujiro Nishida
Koujiro Nishida
HSHideto Sonoda
Hideto Sonoda
YYYasuji Yoshikawa
Yasuji Yoshikawa
MMMasaki Mori
Masaki Mori